thecommission can launch a europe wide of evaluation european medicines agency in two cases firstly member states divergent national decisions concerning a marketing authorization and
The Commission can launch a Europe-wide evaluation by the European Medicines Agency in two cases: firstly, when Member States adopt divergent national decisions concerning a marketing authorisation and, secondly, before any decision is reached on the granting, variation, suspension or revocation of a marketing authorisation that appears necessary, in particular, when taking account of pharmacovigilance information in cases where it considers that the interests of the Community are involved.
The Commission can launch a Europe-wide evaluation European Medicines Agency in two cases: firstly, Member States divergent national decisions concerning a marketing authorisation and, secondly, before any decision is reached the granting, variation, suspension or revocation of a marketing that appears necessary, in particular, taking account of pharmacovigilance in cases where it considers that the interests of the Community are